Abstract
We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
Original language | English |
---|---|
Pages (from-to) | 557-559 |
Number of pages | 3 |
Journal | Journal of Korean medical science |
Volume | 22 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2007 |
Externally published | Yes |
Keywords
- Cytochrome P-450 CYP2C9
- Pharmacogenetics
- Polymorphism
- Prothrombin time
- Warfarin
ASJC Scopus subject areas
- Medicine(all)